Cantor Fitzgerald launched coverage of Cognition Therapeutics (NASDAQ:CGTX) with an “overweight” rating and 12-month price target of $12. The stock closed at $1.74 on Sept. 28. Cognition is a neuro-innovator leveraging...
William Blair launched coverage of Akouos (NASDAQ:AKUS) with an “outperform” rating and fair value estimate of $12. The stock closed at $5.10 on Sept. 28. Akouos is developing a pipeline of gene therapies delivered...
Stifel downgraded PhaseBio Pharmaceuticals (NASDAQ:PHAS) to “hold” from “buy” and slashed its price target to $1 from $15, citing an ownership dispute over PhaseBio’s bentracimab, a potential ticagrelor reversal agent...
Maxim Group initiated coverage of BioRestorative Therapies (NASDAQ:BRTX) with a “buy” rating and $6 price target. The stock closed at $2.46 on Sept. 27. BioRestorative is a cell therapy company developing BRTX-100 for...
In a new research report, Cantor Fitzgerald writes that Hepion Pharmaceuticals (NASDAQ:HEPA) is a company that has largely flown under the radar despite already achieving some early proof-of-concept evidence and having...
William Blair upgraded Larimar Therapeutics (NASDAQ:LRMR) to “outperform” after the FDA approved the company’s proposed Phase 2 study design for CTI-1601 in Friedreich’s ataxia (FA), enabling a return to clinical...
H.C. Wainwright launched coverage of Everest Medicines (HKSE:1952.HK) with a “buy” rating and price target of $30 HK. The stock closed at $10.38 HK on Sept. 8. Everest Medicines is an integrated biopharmaceutical...
BTIG initiated coverage of Annexon (NASDAQ:ANNX) with a “buy” rating and $15 price target. The stock closed at $6.02 on Sept. 8. Annexon, Inc. is a development-stage biotech company focused on mediating the role of...
Cantor Fitzgerald initiated coverage of Asensus Surgical (NYSE American:ASXC) with an “overweight” rating and price target of $1.50. The stock closed at 53 cents on Sept. 7. Asensus is a robotic-assisted surgery company...
Cantor Fitzgerald launched coverage of Actinium Pharmaceuticals (NYSE American:ATNM) with an “outperform” rating and $20 price target. The stock closed at $7.51 on Sept. 7. Actinium is a clinical-stage biopharmaceutical...
Piper Sandler launched coverage of Miromatrix Medical (NASDAQ:MIRO) with an “overweight” rating and $8 price target. The stock closed at $2.92 on Aug. 30. Miromatrix has developed a proprietary perfusion technology...
Dawson James initiated coverage of Smart for Life (NASDAQ:SMFL) with a “buy” rating and $8 price target. The stock closed at 53 cents on Aug. 26. The company’s goal is the development, marketing, manufacturing...
SVB Securities launched coverage of Moonlake Immunotherapeutics (NASDA:MLTX) with an “outperform” rating and $17 price target. The stock closed at $9.01 on Aug. 24. Moonlake is a clinical-stage biopharmaceutical company...
Ladenburg Thalmann initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $6.50. The stock closed at 13 cents on Aug. 24. Kiora is focused on bringing treatments to the market...
Maxim Group downgraded Aridis Pharmaceuticals (NASDAQ:ARDS) to “hold” from “buy” and removed its price target, citing capital concerns and key clinical programs. The stock closed at $2.19 on Aug. 15. In a 10-Q report...
Dawson James Securities slashed its price target for Aditxt Therapeutics (NASDAQ:ADTX) to $1 from $6, but maintained a “buy” rating, noting that cash is tight and a capital raise is expected. The stock closed at 17...
Stifel downgraded IDEAYA Biosciences (NASDAQ:IDYA) to “hold” from “buy” and reduced its price target to $13 from $16 “on the belief that it’s difficult to gain high conviction in the MTAP/MAT2A thesis (we ascribe...
Cantor Fitzgerald initiated coverage of Mereo BioPharma (NASDAQ:MREO) with an “overweight” rating and $4 price target. The stock closed at $1.15 on Aug. 11. Mereo is a clinical-stage biopharmaceutical company that is...
BTIG reduced its price target for Pear Therapeutics (NASDAQ:PEAR) to $5 from $11 but maintained its “buy” rating after the company missed second quarter revenue consensus and lowered 2022 revenue guidance. The stock...
Cantor Fitzgerald downgraded TerrAscend (OTCQX:TRSSF) to “neutral” from “overweight” and reduced its price target to $2.85 from $6.45 on lower estimates and sectoral derating. The stock closed at $2.40 on Aug. 11...
SVB Securities downgraded 4D Molecular Therapeutics (NASDAQ:FDMT) to “market perform” from “outperform” and reduced its price target to $12, citing an elevated risk to the lead Fabry disease program, along with an...
BTIG raised its price target for Acutus Medical (NASDAQ:AFIB) to $2.50 from $1.50 after the company beat consensus estimates for second quarter revenue. The stock closed at $1.66 on Aug. 11. Acutus Medical is a cardiac...